Quick Answer
Denali Therapeutics Inc. reported R&D Expense of $418.78 million for fiscal year 2025.
Denali Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $418.78M | +5.6% |
| 2024 | $396.44M | -6.5% |
| 2023 | $423.88M | +18.2% |
| 2022 | $358.73M | +35.2% |
| 2021 | $265.35M | +24.8% |
| 2020 | $212.62M | +9.9% |
| 2019 | $193.38M | +35.1% |
| 2018 | $143.18M | +92.3% |
| 2017 | $74.46M | -1.6% |
| 2016 | $75.70M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $101.95M | +3.8% | -0.7% |
| June 30, 2025 | $102.70M | +12.4% | -11.6% |
| March 31, 2025 | $116.23M | +8.6% | +18.3% |
| September 30, 2024 | $98.24M | +9.5% | +7.5% |
| June 30, 2024 | $91.40M | -6.3% | -14.6% |
| March 31, 2024 | $107.02M | -16.9% | +19.3% |
| September 30, 2023 | $89.74M | +2.2% | -8.0% |
| June 30, 2023 | $97.52M | +5.2% | -24.3% |
- Denali Therapeutics Inc. showed an increase of +5.6% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, Denali Therapeutics Inc.’s r&d expense has grown by 453.2% (from $75.70 million to $418.78 million).
- The most recent figure is from Denali Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: